Current therapy for advanced prostate cancer is mainly based on androgen deprivation, although most patients relapse to androgen-insensitive disease. Several mechanisms contributing to androgen-independent growth including alterations in the structure or expression of the androgen receptor (AR) and its cofactors have been identified. Recent evidence suggests that p53 is involved in androgen signaling. The analysis of the effect of p53 on androgen signaling was performed in 22Rv1 and LNCaP prostate cancer cells that express both p53 and AR. The overexpression of p53 diminished the androgenic response in both cell lines in a reporter gene assay. Conversely, the inhibition of p53 by three different p53 inhibitors, Pifithrin-1a (PFT-1a), an inhibitor of p53-dependent transactivation; MDM2, a regulator of p53 expression; and a dominant-negative N-terminally truncated p53 gene also reduced transactivation of androgen-dependent reporter genes. The inactivation of p53 by PFT-1a decreased AR-protein expression in both 22Rv1 and LNCaP cells. Our findings confirm that the overexpression of wild-type p53 decreases androgen function, whereas p53 expression at physiological levels stabilizes AR signaling. Thus, our findings suggest that there is a balance of AR and p53 expression during the androgendependent growth of prostate cancer, which is obliterated during further progression of the disease.
Introduction
As prostate cancer cells depend on androgens for growth and survival, androgen ablation is a standard treatment for patients suffering from metastatic prostate cancer. Androgen withdrawal causes cancer regression by decreasing cell proliferation and increasing apoptosis. However, most metastatic prostatic carcinomas progress to a state of disease insensitive to androgen ablation (Feldman and Feldman, 2001) . Several mechanisms contributing to androgen-independent progression have been identified including alterations in the structure, expression, and regulation of the androgen receptor (AR) (Culig et al., 1993; Cronauer et al., 2000; Feldman and Feldman, 2001 ). The AR is expressed in a high proportion of metastatic prostate cancers. In rare cases, the receptor is mutated (Culig et al., 1993; Feldman and Feldman, 2001) . In other cases, the overexpression of AR and/or changes in the expression of different cofactors are observed, which may confer increased sensitivity of the AR to low levels of circulating androgens (Feldman and Feldman, 2001) .
Further changes permitting prostate carcinoma cells to overcome the effects of androgen ablation occur in pathways regulating apoptotic cell death. One pertinent alteration is mutation of the p53 gene in prostatic tumor cells. The p53 tumor suppressor gene encodes a nuclear transcription factor, which is activated and which accumulates in the cells in response to a variety of stresses inducing growth arrest or apoptosis. Loss of p53 function may compromise the ability of carcinoma cells to undergo apoptosis in response to genomic instability, thereby favoring the accumulation of genetic changes responsible for androgen independence. In prostate cancer, alterations in the p53 tumor suppressor gene are clearly associated with progressive disease, like metastases to bone-and androgen-independent growth (Navone et al., 1993; Aprikian et al., 1994; Eastham et al., 1995; Meyers et al., 1998; Burchardt et al., 2001) .
There is increasing evidence that p53 may also directly regulate androgen signaling. The p53 protein has been shown to interact with several steroid receptors including the AR (Yu et al., 1997a, b; Sengupta and Wasylyk, 2001; Shenk et al., 2001) . The overexpression of wildtype p53 in PC-3 cells decreased transactivation of the PSA promoter by the AR in a cotransfection reporter assay (Shenk et al., 2001) . However, interpretation of this experiment is complicated by the fact that PC-3 cells normally express neither p53 nor AR and do not tolerate the expression of either protein over a prolonged period of time (Isaacs et al., 1991; Srivastava et al., 1995; Heisler et al., 1997; Eastham et al., 2000; Schumacher et al., 2001) . Another study showed that the transfection of one specific mutant p53, R175H, thought to inhibit wild-type p53 function actually increased androgen-dependent induction of PSA in LNCaP cells, which express both wild-type p53 and AR (Gurova et al., 2002) . A different study showed that the downregulation of wild-type p53 function by an antisense approach conferred a hormone-resistant phenotype to LNCaP cells in nude mice (Burchardt et al., 2001) .
A major problem in the analysis of AR signaling is that under normal conditions, epithelial cell lines as well as primary epithelial cell cultures rarely express AR protein (Peehl, 1994; Cronauer et al., 1997) . In addition to LNCaP, only few cell lines expressing AR protein have been described (Navone et al., 1993; Peehl, 1994; Sramkoski et al., 1999; Lee et al., 2001; Sinisi et al., 2002) . In a systematic analysis of the literature on ARpositive cell strains, we noted that almost all prostate cancer cell lines expressing AR also express wild-type p53 (Table 1) . This observation prompted us to analyse the effects of the dysregulation of endogenous p53 on AR signaling in prostate cancer cell lines.
As the overexpression of p53 downregulates the androgenic response, one would predict that the inhibition of endogenous wild-type p53 should upregulate the androgenic response in prostatic cells. Therefore, we employed three different inhibitors of p53, Pifithrin-1a (PFT-1a), an inhibitor of p53-dependent transactivation (Komarov et al., 1999) ; MDM2, which interacts directly with p53 promoting its ubiquitylation and proteasomal degradation (Momand et al., 1992; Grossman et al., 1998) ; and a dominant-negative Nterminally truncated p53 (Shaulian et al., 1992) . The effect of these p53 inhibitors on androgen response and cell growth were studied in LNCaP and 22Rv1 cells, which express both AR and p53 (Peehl, 1994; Sramkoski et al., 1999) .
In accord with previous findings, the overexpression of wild-type p53 in 22Rv1 and LNCaP cells resulted in a dramatic decrease in transactivation of androgeninducible gene promoters by the AR. In addition, we showed physiologically induced levels of p53 to be sufficient for this inhibition. Surprisingly, however, treatment of 22Rv1 or LNCaP cells with p53 inhibitors did not increase transactivation by the AR. Instead, treatment of these cell lines with PFT-1a, an inhibitor of p53, reduced transactivation of the probasin and PSA promoters by the AR. Moreover, the expression of a dominant-negative p53 (pCMVDD) as well as the overexpression of MDM2 (pCMVhMdm2), a negative regulator of p53, repressed androgen-induced transactivation of the probasin promoter plasmid as well. These effects of pCMVDD and PFT-1a on AR-dependent transactivation were strongly p53 dependent, as transfection or treatment of p53-null cells with pCMVDD or PFT-1a had no or only little effect on AR signaling. Most interestingly, subsequent analysis of AR protein revealed that the inactivation of p53 function resulted in a downregulation of AR-protein expression in androgen-stimulated 22Rv1 and LNCaP cells.
Our findings suggest that wild-type p53 at basal physiological levels is necessary for AR signaling and, in fact, has a protective effect on AR-signaling, whereas induced levels block it. Our findings support the concept of a balance between AR and p53 expression during androgen-dependent cell growth and highlight the importance of p53 as a modulator of AR signaling in prostate cells.
Results
In our study, we used the androgen-sensitive LNCaP and the partially androgen-sensitive 22Rv1 prostate cancer cell lines. LNCaP are fully androgen sensitive, that is, exhibit androgen-dependent growth and secrete PSA in response to androgens. 22Rv1 grow in an androgen-independent manner but express a functional AR. In a first series of experiments, we confirmed that 22Rv1 express both AR and p53 (Figure 1a and b) . In contrast to LNCaP cells, 22Rv1 cells expressed not only a full-length AR (110 kDa) but also a truncated 78 kDa (Tepper et al., 2002) . To confirm that the AR in 22Rv1 cells is able to transactivate androgen-dependent genes, 22Rv1 cells were transfected with an androgenresponsive probasin-luciferase reporter plasmid. In the presence of 10 nM methyltrienolone (R1881), a synthetic androgen, probasin-promoter activity increased threefold in 22Rv1 cells compared to 25-fold in LNCaP cells ( Figure 2 ). The typical induction of wild-type p53 expression as a result of exposure to the DNA-damaging agent cisplatin was confirmed in both cell lines by Western Blotting (Figure 1b) . In both LNCaP and 22Rv1 cell lines, the transfection of wild-type p53 diminished androgen-induced probasin-luciferase reporter activity (Figures 2 and 3a) . Of note, in these experiments, p53 was expressed by a retrotransposon promoter that yields only about 10% the expression levels that are induced by other viral promoters, thus avoiding extremely supraphysiological levels of p53 (Steinhoff et al., 2002) . To analyse the effects of endogenously induced levels of p53 on AR signaling, we treated 22Rv1 cells with cisplatin. The induction of endogenous p53 by 2.5 or 5 mg/ml cisplatin led to a subsequent 67-80% decrease in AR-mediated transactivation of the probasin-luciferase reporter (Table 3) .
In order to prove that the downregulation of AR signaling in prostate cancer cells can be initiated by physiologically induced levels of p53, we performed a series of experiments in PC-3 prostate cancer cells that do not express p53 (p53-null cells). To analyse the effects of different levels of p53 on AR signaling, PC-3 cells were transfected with an AR expression plasmid (pSG5-AR) together with a probasin-reporter plasmid and pMThup53, in which p53 expression is controlled by the zinc-inducible mouse MT-1 metallothionein promoter (Makri et al., 1998) . Treatment with ZnCl 2 induces the weak MT-1 promoter approximately fivefold (Hasse et al., 1992) . Cells transfected with pMT-CAT (Hasse et al., 1992) , instead of pMThup53, served as controls. Low levels of p53 expressed from the uninduced MT promoter did not interfere with transactivation of the probasin promoter by AR, and appeared, in fact, slightly stimulatory. Following induction of p53 by ZnCl 2 , however, pMThup53-transfected PC-3 cells showed a significantly lower AR activity than either cells not treated with ZnCl 2 or PC-3 cells transfected with the pMT-CAT control plasmid instead of pMThup53 (Figure 4a ). Taken together, these data show that not only supraphysiological levels of p53 used in previous reports but also levels reached during physiological induction are able to reduce AR-mediated signaling.
As p53 downregulated the androgenic response upon induction, one would predict that the inhibition of endogenous wild-type p53 should upregulate the androgenic response in prostate cancer cells. Therefore, we analysed the effects of different p53 inhibitors on AR signaling. First, we tested PFT-1a, a pharmacological compound that has been reported to reduce transactivation of p53-dependent genes in various cell types including prostate cancer cell lines (Komarov et al., 1999; Javelaud and Besancon, 2002; Lin et al., 2002a; Kelly et al., 2003) . Treatment with 20 mM PFT-1a inhibited the induction of probasin-luciferase activity by androgen (10 nM R1881) by 95% in LNCaP and by 96% in 22Rv1 cells (Figure 2) . Moreover, PFT-1a was unable to restore the AR response in cells transfected with pLinep53 (Figure 2 ). In summary, in cell lines expressing wild-type p53, both inhibition of p53 by PFT-a as well as the overexpression of p53 downregulated the androgenic response.
As the effects of PFT-1a on p53 might not only limit the response to androgens but might also alter the rate of cell proliferation and apoptosis, we analysed the effects of PFT-1a on DNA synthesis and apoptosis in prostate cancer cell lines. DNA synthesis was determined by measuring BrdU incorporation. PFT-1a reduced DNA synthesis in PC-3, 22Rv1 and LNCaP cells. In the absence of androgens, PFT-1a (20 mM) lowered BrdU incorporation in PC-3, 22Rv1, and LNCaP by 15, 13, and 54%, respectively. In the presence of R1881 (0.1 nM), BrdU incorporation was reduced by 18, 12, and 30%, respectively (Table 2a) . Although the antiproliferative effects of PFT-1a were most pronounced in LNCaP, which grows in an androgen-dependent manner, the compound also reduced DNA synthesis in 22Rv1 and PC-3, which do not. Moreover, it is important to note that PFT-1a exhibited slight antiproliferative effects in PC-3 cells that are known not to express p53 -protein, suggesting that PFT-1a not solely acts through an inhibition of p53.
The rate of apoptosis was determined by the measurement of caspase-3/7 activity. Caspase activity in cells grown without androgens but in the presence of PFT-1a (20 mM) was reduced by 25% in LNCaP and was increased by 13% in 22Rv1 cells. Caspase-3/7 activity also increased at higher concentrations of R1881. Treatment with 10 nM R1881 increased caspase activity in 22Rv1 and LNCaP cells by 120 and 230%, respectively. Coincubation with PFT-1a (20 mM), in (Table 2b ), except at the highest concentration of R1881 (10 nM) in LNCaP cells. In summary, these findings on the one hand confirm previous observations that high androgen concentrations are associated with higher rates of spontaneous apoptosis in LNCaP cells (Coffey et al., 2002) . On the other, they demonstrate that the dramatic decrease in the AR response after PFT-1a treatment is not due to increased apoptosis.
To ensure that the PFT-1a effect on androgenic signaling was predominantly due to its inhibitory action on p53, we analysed the consequences of p53 downregulation on AR signaling by the transfection of further p53 inhibitors. For these experiments, we used 22Rv1 cells, which can be transfected at a greater efficiency than LNCaP cells. Like treatment with PFT-1a (Figure 2 ), the transfection of MDM2 (pCMVhMdm2) downregulated both basal-and androgen-induced activity of the probasin promoter (Figure 3b) . Likewise, transfecting a dominant-negative truncated p53 (pCMVDD) to disrupt endogenous p53 signaling resulted in strongly diminished transactivation of the probasin promoter in 22Rv1 (Figure 3c ). The effects of pCMVDD on probasin promoter activity were comparable in magnitude to those seen with PFT-1a treatment.
In order to ensure that the effects of PFT-1a and pCMVDD were not specific to the probasin promoter, additional experiments were performed with a PSAluciferase reporter plasmid (pPSA61-luc) ( Figure 5 ). As in the experiments with the probasin-reporter plasmid, PFT-1a and pCMVDD caused a downmodulation of AR-mediated transactivation of the PSA promoter. This indicates that the disruption of p53 function has a generalized effect on AR transactivation in 22Rv1 cells (Figure 5a and b) .
In order to prove that the downregulation of AR signaling in prostate cancer cells by PFT-1a and pCMVDD was indeed mediated through their effects on p53, we performed a series of experiments in PC-3 prostate cancer cells that are p53-null cells. The transfection of a pCMVDD had no effect on AR signaling in PC-3 cells that do not express endogenous p53. PFT-1a reduced AR transactivation in PC-3 cells by 30%. This 30% reduction is minimal compared to the downmodulation of AR signaling by 495% in p53-positive cell lines (Figure 2) , and suggests that the major part of the PFT-1a effect on AR signaling is due to its inhibitory function on p53 (Figure 4b) .
To investigate the effects of p53 inhibition on AR expression, LNCaP and 22Rv1 cells were treated with/ without R1881 (10 nM) in the presence/absence of PFT1a for 48 h. Subsequently, AR expression was determined by Western blotting (Figure 6 ). When grown in the presence of R1881, PFT-1a-treated LNCaP and 22Rv1 cells clearly exhibited a downregulation of their AR protein in comparison to untreated controls, suggesting a direct effect of p53 on AR-protein expression ( Figure 6 ).
Discussion
There is little doubt that steroid hormone receptors can be added to the continually growing list of proteins with Table 2 Effects of PFT-1a and R1881 on (a) BrdU incorporation (% of untreated controls that were set at 100%7s.d.) and (b) caspase-3/7 activity (% of untreated controls that were set at 100%7s. which p53 directly interacts (Yap et al., 1996; Yu et al., 1997a, b; Shenk et al., 2001) . Interactions of p53 with estrogen, glucocorticoid, and thyroid receptors are well established (Yap et al., 1996; Yu et al., 1997a, b) . Overexpressed p53 represses AR induction of the PSA gene, although direct binding of p53 to the AR has not been demonstrated (Shenk et al., 2001) . The ability of p53 to modulate AR-mediated transcription was initially studied in cotransfection assays using the human prostate cancer cell line, PC-3, which expresses neither p53 nor AR (Carroll et al., 1993; Peehl, 1994; Rubin et al., 1991) . Interpretation of these results is complicated by the fact that PC-3 cells do not tolerate longterm expression of either protein in vitro (Heisler et al., 1997; Jacobberger et al., 1999; Eastham et al., 2000; Schumacher et al., 2001) . Thus, the repression of ARmediated transcription by p53 is achieved in a transient state in cells that are likely to be destined for cell death. A second study on this issue reported that the transfection of one specific mutant p53 (R175H) increased the induction of PSA in LNCaP cells, which contain functional AR and wild-type p53 (Gurova et al., 2002) . Only this mutant, but none of the others, exhibited this effect, which the authors ascribed to a dominant-negative function of this particular mutant (Gurova et al., 2002) . However, the function of R175H in different cell types is controversial. It is certainly debatable to regard R175H simply as a dominantnegative inhibitor of p53 (Pocard et al., 1996; Coursen et al., 1997; Kremenetskaya et al., 1997; Gurova et al., 2002; Shi et al., 2002) . Specifically, R175H is known to induce the cytokine interleukin 6 (IL-6) in different cell systems (Runnebaum et al., 1994; Asschert et al., 1999) . Recent studies have demonstrated that IL-6 is a potent inducer of AR signaling in LNCaP cells (Hobisch et al., 1998; Chen et al., 2000; Culig et al., 2002) . Therefore, it remains to be elucidated whether the increased induction of PSA in LNCaP cells after transfection with mutant p53, R175H, is due to the inhibition of p53-AR interaction, to induction of IL-6, or to other mechanisms. Accordingly, the overexpression of several p53 mutants frequent in advanced prostate cancer (G245S, R248W, R273H, and R273C) was recently shown not to increase PSA in stably transfected LNCaP cells (Nesslinger et al., 2003) .
Here, we confirmed that that the 22Rv1 prostate carcinoma cell line like the LNCaP cell line expresses AR and p53 (Figure 1 ). In agreement with a recent report (Tepper et al., 2002) , we found that 22Rv1 cells express, in contrast to LNCaP cells, not only a fulllength AR but also a truncated form of the AR. Androgen sensitivity of 22Rv1 cells was demonstrated by transfection assays with two different androgenresponsive reporter plasmids (pPSA61-luc, pGL3Eprob) ( Figure 5 ).
Using different cotransfection assays, we confirmed that the overexpression of p53 blocks androgen signaling in 22Rv1, LNCaP, and PC-3 cells (Figures 2, 3a , and 4). In order to mimic physiological levels of p53, we used p53 expression vectors under the control of different promoters (i.e. Line, MT), which yield only about 1-10% the expression levels of the usual viral promoters (Hasse et al., 1992; Steinhoff et al., 2002) , thus avoiding extremely supraphysiological levels of p53 achieved in other studies (Shenk et al., 2001) . Moreover, physiological induction of p53 with cisplatin in 22Rv1 cells was sufficient to block androgen signaling in these cells (Figure 1b, Table 3 ). Our results indicate for the first time that typically induced levels of p53 can interfere with AR function.
However, our data show that basal levels of p53 have a very different effect. If basal levels of wild-type p53 were limiting for androgen responses, one would expect inhibitors of p53 to increase androgen signaling. Surprisingly, three different treatments aimed at inhibiting endogenous p53 decreased rather than increased androgenic responses in these cell lines.
PFT-1a, a synthetic reversible inhibitor of p53 in various cell types including prostate cancer cells (Lin et al., 2002a; Kelly et al., 2003) , dramatically inhibited the induction of probasin-luciferase activity and PSAluciferase activity in LNCaP and 22Rv1 cells. One might attribute this finding to toxic effects of PFT-1a unrelated to p53. The analysis of the effect of PFT-1a on the proliferation of different prostate cancer cell lines indeed showed that PFT-1a to some extent negatively affected (Table 2a) . This finding is supported by a recent paper reporting PFT-1a not to act solely through p53-dependent mechanisms (Komarova et al., 2003) . However, its moderate inhibitory effects on cell growth and apoptosis cannot account for the 90% decrease in androgen signaling caused by the compound. Nevertheless, the specific inhibitory effect on p53 signaling may appear exaggerated due to toxic effects of the compound. Therefore, additional experiments with other p53 inhibitors were crucial. Thus, we used a pCMVDD that represents the C-terminal residues 302-390 of wild-type p53 preceded by 14 N-terminal residues of wild-type p53 (Shaulian et al., 1992) . In contrast to mutated p53 R175H, pCMVDD is a bona fide dominant-negative inhibitor of p53 that inhibits p53 DNA-binding activity, thereby disrupting endogenous p53 signaling (Shaulian et al., 1992) . Like PFT-1a, this pCMVDD strongly inhibited transactivation of the probasin and PSA promoters (Figures 3c and 5 ). The effects were comparable in magnitude to those obtained by PFT-1a, thereby confirming that the effects of PFT1a on androgen signaling cannot be attributed to toxic effects unlinked to p53. This observation is furthermore supported by the fact that the same pCMVDD had no effect on AR signaling in PC-3 cells, which are p53-null ( Figure 4b) . Similarly, PFT-1a reduced AR transactivation in PC-3 cells by only 30% (Figure 4b) . A recent clinical study suggested that MDM2 overexpression is a frequent mechanism of p53 inactivation in prostate cancer (Osman et al., 1999) . The transfection of MDM2 into 22Rv1 cells downregulated basal as well as androgen-induced activity of the probasin promoter, albeit not as pronounced as pCMVDD or PFT-1a (Figure 3b) . Recently, it has been demonstrated that MDM2 is essential for Akt-mediated ubiquitylation and degradation of the AR in vitro (Lin et al., 2002b) . As the MDM2 gene is itself under transcriptional control of p53, creating an autoregulatory feedback loop, it is conceivable that p53 may control AR-protein levels and its activation indirectly via MDM2.
Our data indeed show that one level at which p53 affects androgen signaling is through the regulation of AR expression or stability. The inactivation of p53 by PFT-1a decreased AR-protein expression in 22Rv1 and LNCaP cells (Figure 6 ). This relationship may explain the strikingly tight relationship between AR expression and expression of wild-type p53 in vitro revealed by a survey of the literature (Table 1) . Most recently, in new androgen-independent prostate cancer cell lines derived from LNCaP via in vitro deprivation (Patel et al., 2000) , low levels of p53 were reported along with almost undetectable levels of PSA mRNA and reduced levels of AR mRNA (Freedland et al., 2003) . Similarly, in breast cancer a consistent relationship appears to exist between the expression of estrogen receptor (ER) and wild-type p53 expression (Caleffi et al., 1994) .
There is little doubt that a overexpression of p53 reduces transactivation of androgen-dependent genes (Shenk et al., 2001; Nesslinger et al., 2003) . However, for the first time, we present experimental evidence that the inactivation of p53 as well diminishes AR-mediated signaling. Our findings suggest that physiological levels of wild-type p53 are necessary and have a protective effect on AR signaling in androgen-responsive prostate cancer cell lines. In contrast, elevated levels of p53 block androgen signaling. Our observations support the concept that androgen-dependent growth of prostate cancer cells occurs at a balanced level of p53 and AR expression. Disruption of this balance may play a crucial role in the progression to androgen-insensitive prostate cancer.
Materials and methods

Plasmids
The probasin-promoter luciferase-reporter plasmid (pGL3E-prob) and the pSG5-AR were a gift from Dr Z Culig, Innsbruck, Austria. The PSA-luciferase plasmid (pPSA61-luc) was supplied by Dr Jan Trapman, Erasmus University, Rotterdam, The Netherlands, via Dr A Baniahmad, University of Giessen, Germany. The pCMVDD and pCMVhMdm2 expression plasmids were kindly provided by Dr M Oren, Weizman Institute of Science, Rehovot, Israel and Dr B Vogelstein, Johns Hopkins University Oncology Center, Baltimore, MD, USA. The pLinep53 plasmid and its corresponding cDNA-less plasmid pLine as well as pMThup53 and pMT-CAT have been described by our laboratory (Hasse et al., 1992; Makri et al., 1998; Steinhoff et al., 2002) .
Tissue culture 22Rv1, LNCaP, and PC-3 prostatic carcinoma cells were routinely maintained in RPMI-1640, supplemented with 10% fetal bovine serum and antibiotics. During experiments, cells were cultured in RPMI-1640 with 2.5% charcoal-treated steroid-free fetal bovine serum, cFBS (PAA Laboratories, Linz, Austria), and antibiotics supplemented with the indicated amounts of the synthetic androgen, milbolerone, R1181 (New England Nuclear, Dreieichenhain, Germany).
Transfection assays
Cells were grown on 24-well plates. The probasin-promoter luciferase-reporter plasmid, pGL3Eprob, was mixed with either pLinep53, pCMVhMdm2 or pCMVDD expression vector, or the respective cDNA-less vectors at a ratio of 1 : 5. pRL-tk-LUC Renilla vector (Promega, Mann-heim, Germany) was used to correct for transfection efficiency. Transfection was performed using FuGene6 (Roche Diagnostics Corporation, Basel, Switzerland), according to the manufacturer's instructions. After an incubation period of 12 h in RPMI-1640 with 5% cFBS, the medium was changed to RPMI-1640 containing 2.5% cFBS, with or without androgens. Reporter activity was assessed after a 30 h incubation period using the Dual-Luciferase Reporter Assay System (Promega, Mannheim, Germany).
Immunoblotting of p53 and AR
Prostate cancer cell lines, 22Rv1 and LNCaP, were cultured in T25 culture flasks for 48 h. Cell protein extracts were prepared as described (Marth et al., 1990) . Protein extracts (30 mg) were electrophoresed through a 7% SDS-PAGE gel and electroblotted onto PVD membranes. Nonspecific binding was blocked by incubating the membrane with 5% nonfat dry milk in phosphate-buffered saline. Afterwards, membranes were exposed to the AR-specific rabbit antiserum PG-21 (Upstate, Lake Placid, NY, USA), or to mouse anti-p53, DO-7 (Sigma, Taufkirchen, Germany) (Cronauer et al., 2000; Burchardt et al., 2001) . Immunoreactive bands were detected with peroxidase-labeled mouse anti-rabbit or anti-mouse antibodies (1 : 5000), respectively. AR and p53 bands were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech, Freiburg, Germany).
Cell proliferation and apoptosis assay
Cellular proliferation was assessed by means of BrdU incorporation during DNA synthesis using a commercial colorimetric BrdU ELISA (Cell Proliferation ELISA, BrdU, Roche Basel, Switzerland). The test was performed according to the manufacturer's instructions.
Caspase-3/7 activity as an indicator of apoptosis was determined using the Apo-ONEt Homogeneous Caspase-3/7 Assay (Promega, Madison, WI, USA). Caspase activity was measured according to the manufacturer's instructions using a Wallac 1420 multilabel counter (Wallac, Turku, Finland) .
